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From 2000 through 2005, hospitalizations with resis-
tant infections (methicillin-resistant Staphylococcus aureus, 
Clostridium difﬁ  cile–associated disease, vancomycin-resis-
tant enterococcus, Pseudomonas aeruginosa, and Candida 
infection) nearly doubled, from 499,702 to 947,393. Region-
al variations noted in the aggregate and by individual in-
fection may help clarify modiﬁ  able risk factors driving these 
infections.
O
ver the past decade we have witnessed a rise in the 
antimicrobial drug–resistance epidemic in the United 
States and worldwide. Not only are resistant organisms such 
as methicillin-resistant Staphylococcus aureus (MRSA) and 
Clostridium difﬁ  cile encountered with increasing frequen-
cy (1,2), but as their susceptibility to antimicrobial agents 
is waning, their overall virulence is on the rise (3,4). Ad-
ditionally, though traditionally thought of as a nosocomial 
pathogen, MRSA, for example, is now a well-recognized 
community-acquired infection (5).
With the rapid growth of resistance, and the added as-
sociated illnesses and deaths (6,7), these infections exert a 
considerable strain on the US healthcare system, speciﬁ  -
cally on hospitals. Although important to understand for 
individual infections, the aggregate volume of resistance is 
an important factor in illustrating the problem as a whole 
and in helping identify the potential resources needed to 
deal with the epidemic. To understand the full extent of 
resistant infections in US hospitals, we examined their lon-
gitudinal trends from 2000 through 2005, focusing further 
on regional patterns of resistance during this time frame.
The Study
We identiﬁ   ed all hospitalizations carrying a diag-
nosis of MRSA, Clostridium difﬁ  cile–associated disease 
(CDAD), vancomycin-resistant enterococcus (VRE), 
Pseudomonas aeruginosa, and Candida infections for 
2000–2005 from the National Inpatient Sample data. These 
data are available on the Healthcare Costs and Utiliza-
tion Project net [HCUPnet] website, administered by the 
Agency for Healthcare Research and Quality (8). We used 
the corresponding diagnosis codes from the International 
Classiﬁ  cation of Diseases, 9th revision, Clinical Modiﬁ  ca-
tion (online Appendix Table, available from www.cdc.gov/
EID/content/14/11/1756-appT.htm). Because few reports 
of vancomycin-resistant Staphylococcus aureus exist (9), 
we assumed that most cases with the code V09.8 represent-
ed VRE infections. We limited hospitalizations in which 
Candida organisms had been identiﬁ  ed to deep-seated in-
fections, including candidiasis of the lung, disseminated 
candidiasis, candidal endocarditis, meningitis, esophagitis, 
and enteritis. The numbers of discharges per year for infec-
tions associated with each organism and in aggregate were 
stratiﬁ  ed by census region. We obtained regional estimates 
of all US hospitalizations in the corresponding years from 
the HCUPNet (8), and censal and intercensal data on the 
US population for 2000–2005 from the US Census Bureau. 
We calculated region-speciﬁ   c hospitalization incidence 
rates associated with the resistant pathogens. Because large 
numbers would predispose the study to type I error, we did 
not perform formal signiﬁ  cance testing; rather, we focused 
on clinical and policy-relevant trends.
The overall volume of resistant infections increased 
by 89.6% from year 2000 through 2005 (Table). As a pro-
portion of the total volume growth, the increases across 
regions were comparable. The southern region had the 
highest raw volume of resistant infections for the study 
period (2000, 37.3%; 2005, 39.1%). The West had the 
smallest contribution in 2000 (19.0%) and 2005 (19.5%). 
However, the Northeast had the highest relative incidence 
per 1,000 hospitalizations with 14.00 in year 2000; its in-
cidence of 19.98 in 2005, however, was lower than that 
in the South, 20.76/1,000 (Table). Regional disparities in 
the population-based incidence of hospitalizations with 
resistant organisms also occurred (Table). Thus, the in-
cidence in the Northeast was not only the highest for 5 
of the 6 years examined, but compared to that seen in the 
lowest-incidence region, the West, was higher by as much 
as 41.9% in 2003. This gap shrank in 2004 and 2005 to 
29.9% and 27.7%, respectively.
When the incidences of individual component infec-
tions were examined, several patterns emerged. While the 
Northeast led other regions in the incidence of CDAD hos-
pitalizations over the entire period examined (Figure, panel 
A), the South exhibited the highest population incidence 
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of MRSA and Pseudomonas hospitalizations. Although 
temporal patterns of regional population incidence varied 
somewhat for hospitalizations in which VRE and Candida 
spp. infections were diagnosed, by year 2005 the Northeast 
emerged as the region with the highest incidence of VRE, 
while the South had the highest incidence of Candida spp. 
hospitalizations. The lowest incidence of VRE hospitaliza-
tions was consistently seen in the southern region in each 
of the studied years. The incidence of hospitalizations with 
pseudomonal infections remained relatively stable region-
ally over time (Figure, panels B, C, D).
Conclusions
We have demonstrated a substantial rise in the abso-
lute number, incidence, and geographic variations across 
the United States in hospitalizations in which infections 
have been caused by pathogens exhibiting antimicrobial re-
sistance. The Northeast consistently outpaced the other re-
gions in the aggregate volume of resistant infections in 5 of 
the 6 years examined. For individual infections, a region’s 
having a relatively high incidence of 1 organism does not 
guarantee it will have a high incidence of another organism, 
as illustrated by the reversal of the regional incidence pat-
terns for MRSA and CDAD, for example. Most troubling, 
however, is the general ﬁ  nding of a ubiquitous, substantial, 
and continuing increase in the incidence of hospitalizations 
with resistant infections.
A notable pattern in our study is that the regions with 
the higher incidence of CDAD (Northeast and Midwest) 
also exhibited higher incidence of VRE in at least half of 
the study period, consistent with the observation that infec-
tion with CDAD can facilitate transmission of VRE (10,11). 
The South had the highest incidence of MRSA and lowest 
incidence of VRE. Since both pathogens share similar risk 
factors, why this pattern should be present is biologically 
unclear (12,13), although a recent report noted a similar 
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Table. Volume, incidence of, and hospitalizations for infections with resistant organisms in the United States, by census region, 2000–
2005
Hospitalizations and incidence  2000 2001 2002 2003 2004 2005
Annual no. hospitalizations
 All  US  499,702 559,728 639,468 699,140 783,601 947,393
 Northeast  102,913 119,799 132,607 151,306 152,881 188,306
 Midwest  115,623 122,122 144,647 161,166 179,547 204,351
 South  186,320 212,450 245,933 256,420 305,822 370,348
 West  94,846 105,357 116,281 130,247 145,353 184,390
Incidence/1,000 hospitalizations
 All  US  13.72 15.05 16.92 18.29 20.27 24.19
 Northeast  14.00 16.17 17.74 20.01 19.98 24.29
 Midwest  13.72 14.10 16.47 18.27 20.14 22.65
 South  13.59 15.04 17.09 17.62 20.76 24.79
 West  13.69 15.07 16.25 17.88 19.74 24.76
Incidence/100,000 population
 All  US  177.08 196.32 222.12 240.71 267.27 320.18
 Northeast  191.76 222.22 244.98 278.51 280.73 345.49
 Midwest  179.27 188.40 222.21 246.63 273.59 310.31
 South  185.27 208.55 238.33 245.54 288.87 344.88
 West  149.45 163.31 177.59 196.33 216.17 270.56
Figure. Population incidence of component 
resistant infections in the United States, by 
census region, 2000–2005. A) Clostridium 
difﬁ  cile–associated disease; B) methicillin-
resistant  Staphylococcus aureus; C) 
vancomycin-resistant enterococcus; D) 
Pseudomonas aeruginosa; E) Candida 
spp.pattern of concomitant increases in MRSA and decreases in 
VRE incidence between 1999 through 2005 (14). This po-
tential inverse relationship should be investigated further. 
Lastly, we noted that, although substantially discrepant re-
gionally, the incidence of hospitalizations with P. aerugi-
nosa infections, consistent with others’ observations, has 
remained relatively stable over the 6-year period (15). We 
cannot illuminate the reasons for the patterns of infection 
incidences we have uncovered. Further studies should en-
compass much more granular geographic data to conﬁ  rm 
our ﬁ  ndings and raise hypotheses to explain them.
The most important limitation of our study is that 
case ascertainment was performed by using administra-
tive coding, rather than clinical and microbiologic data, 
and we were unable to verify diagnostic accuracy either 
across time or geographic areas; therefore, the observed 
increases may be partially due to increased awareness of 
resistance. However, administrative coding has been used 
to track the epidemiology of both MRSA and CDAD (1,2). 
Furthermore, temporal trends in case volume are similar to 
trends reported from clinical studies. At least a proportion 
of the case-patients we identiﬁ  ed likely had overlapping 
infections with multiple organisms. Nevertheless, the ag-
gregate number of infections that we have described has 
implications for hospital resource use because persons with 
multiple infections likely require more care than those with 
a single pathogen. Finally, we were unable to differentiate 
between community-acquired and nosocomial infections.
In summary, we have demonstrated a notable increase 
in the incidence of hospitalizations with resistant organisms 
in the United States. Regional variations in the incidence 
may yield clues for future research efforts to ascertain what 
modiﬁ  able risk factors drive decreases in the incidence of 
these deadly infections. The nearly 1 million annual hospi-
talizations in 2005 with resistant infections and their relent-
less upward trajectory in the United States are undesirable 
and unsustainable. Aggressive and coordinated efforts to 
reduce inappropriate use of antibimicrobial agents in hu-
mans and livestock and to encourage development of novel 
therapeutics are urgently needed to stem this public health 
hazard in the United States and throughout the world.
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